Standard BioTools Elects New Directors, Updates Exec Pay

Ticker: LAB · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1162194

Standard Biotools Inc. 8-K Filing Summary
FieldDetail
CompanyStandard Biotools Inc. (LAB)
Form Type8-K
Filed DateNov 7, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation, governance

TL;DR

Standard BioTools adds Rothberg & Harding to board, signs new deals with CEO & CFO.

AI Summary

Standard BioTools Inc. announced on November 6, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Jonathan M. Rothberg and Mr. David E. R. Harding, to its Board of Directors, effective immediately. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Ms. Sarah H. Harrington, and its Chief Financial Officer, Mr. Michael A. G. Johnson, detailing their compensation packages.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.

Risk Assessment

Risk Level: medium — Changes in board and executive compensation can indicate strategic shifts or internal adjustments that may carry inherent risks.

Key Players & Entities

  • Standard BioTools Inc. (company) — Registrant
  • Dr. Jonathan M. Rothberg (person) — Newly Elected Director
  • Mr. David E. R. Harding (person) — Newly Elected Director
  • Ms. Sarah H. Harrington (person) — Chief Executive Officer
  • Mr. Michael A. G. Johnson (person) — Chief Financial Officer
  • November 6, 2024 (date) — Date of earliest event reported

FAQ

Who were the new directors elected to Standard BioTools Inc.'s Board?

Dr. Jonathan M. Rothberg and Mr. David E. R. Harding were elected as new directors.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on November 6, 2024.

What specific items are covered in this Form 8-K filing?

This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.

What is the principal executive office address for Standard BioTools Inc.?

The principal executive office is located at 2 Tower Place, Suite 2000, South San Francisco, California 94080.

What is the former name of Standard BioTools Inc.?

The former name was Fluidigm Corp, with a date of name change on November 13, 2001.

Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-11-07 08:06:29

Key Financial Figures

  • $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob

Filing Documents

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Standard BioTools Inc., dated November 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 7, 2024 STANDARD BIOTOOLS INC. By: /s/ Michael Egholm, Ph.D. Name: Michael Egholm, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.